Methylprednisolone has achieved a clinically acceptable split between glucocorticoid activity and undesired mineralocorticoid activity. Weight for weight, methylprednisolone has five times the anti-inflammatory activity of hydrocortisone and 1.25 times the anti-inflammatory activity of prednisolone but, unlike the latter two corticosteroids, has virtually no mineralocorticoid activity; therefore, the risk of mineralocorticoid-induced side effects is relatively low.